FDA Weighs Stronger Warnings for Antidepressants in Pregnancy Amid Fierce Debate

A push to add new warnings to antidepressants during pregnancy has gained momentum within the FDA. Dr. Tracy Beth Hoeg, a senior regulator, is accelerating the review of a petition filed by Dr. Adam Urato, a maternal-fetal medicine specialist. The proposed changes have sparked debate among medical professionals about the risks of untreated pregnancy-related depression versus potential medication dangers.

Dr. Urato is urging the FDA to introduce a boxed warning—the agency's strongest alert—for SSRIs, the most widely prescribed antidepressants. His petition highlights possible links to miscarriages, fetal brain abnormalities, and developmental disorders like autism. Over 15% of U.S. women, around 26 million, currently take depression medication, with existing guidelines calling SSRIs generally safe in pregnancy.

Researchers reviewing Urato's claims argue that many studies linking SSRIs to autism and other conditions fail to account for other health factors. Dr. Jennifer Payne, a reproductive psychiatrist, warned that a black box warning could deter both doctors and patients from using antidepressants, ignoring the dangers of untreated maternal mental illness. Meanwhile, Dr. Amritha Bhat, a perinatal psychiatrist, supports further research but stresses the need to keep treatment options available for pregnant women with depression.

Hoeg has taken direct action to speed up the process, pushing FDA staff to reduce the review period from nine months. Critics, however, question her involvement due to a perceived conflict of interest with Urato. The agency must now respond in writing, either approving or rejecting the petition with a detailed explanation.

The FDA's decision could reshape how antidepressants are prescribed during pregnancy. A warning may lead some women to stop medication abruptly, risking severe consequences from untreated depression. The outcome will depend on whether the agency finds sufficient evidence to justify the proposed changes.